Lallemand
Americas
Montreal
,
Canada
Multinational
FOUNDED
1903
HEADCOUNT
1001-5000
FUNDING
Privately held
Keywords:
fermentation, precision_fermentation, yeast, bacteria, filamentous_fungi, probiotics, postbiotics, biofuels, nutraceuticals, flavors, fragrances, phenolics, biostimulants, fertilizers, crop_protection, metabolic_engineering, cosmetics, vitamins, food_protein, animal_nutrition, microbiome
BUSINESS
Privately held global microbiology company specializing in the development, production, and marketing of yeasts, bacteria, fungi, and their derivatives. The company has approximately 5,000 employees across 45+ countries and 48 production plants. In December 2023, Lallemand acquired Swiss precision fermentation firm Evolva for CHF 20M (~$23.5M), adding yeast-based precision fermentation technology used for products including Hevani natural vanillin, Veri-te resveratrol, and Valencene/Nootkatone aroma components.
BIOTECH INVOLVEMENT
Operates a proprietary collection of thousands of yeast and bacterial strains supporting industrial fermentation production across baking, brewing, wine, distilling, biofuels, animal nutrition, probiotics, and plant care markets. The Evolva acquisition added precision fermentation capability for higher-value molecules including flavors, fragrances, and health ingredients; the Lallemand Pharma unit produces the PMBL immunostimulant drug and the Healsea postbiotic derived from proprietary marine bacterial fermentation.
TECHNOLOGY PLATFORM
yeast and bacterial fermentation
PRIMARY PRODUCTS
Yeasts; bacterial cultures; probiotics; bio-ingredients; starter cultures